Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSCYF: Alendronate in Cystic Fibrosis Osteoporosis
NCT01812551Phase 3Completed
- Sponsor
- Istituto Auxologico Italiano
- Start
- Oct 2002
- Primary completion
- Jul 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in osteoporosis comparing Alendronate with Placebo (2 arms). Primary endpoint: Bone mineral density increase at lumbar spine at 24 months. Started Oct 2002; status: completed.
02
Drugs
alendronate
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT01812551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01812551.